Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded and Placebo-Control Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above

NCT07285278 is registered in ClinicalTrials.gov with Suzhou Abogen Biosciences Co., Ltd. as lead sponsor.

NCT NCT07285278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07285278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded and Placebo-Control Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
Lead sponsor
Suzhou Abogen Biosciences Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 15, 2025
Completion date
February 15, 2027
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

varicella-zoster virus